Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (EMERGE)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2017 by Biogen
Sponsor:
Information provided by (Responsible Party):
Biogen
ClinicalTrials.gov Identifier:
NCT02484547
First received: June 18, 2015
Last updated: April 6, 2017
Last verified: April 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: April 30, 2022
  Estimated Primary Completion Date: February 19, 2020 (Final data collection date for primary outcome measure)